EA200700614A1 - Фармацевтическая композиция, содержащая микрокапсулы статинов, суспендированные в алкиловых эфирах полиненасыщенных жирных кислот ( pufa ) - Google Patents

Фармацевтическая композиция, содержащая микрокапсулы статинов, суспендированные в алкиловых эфирах полиненасыщенных жирных кислот ( pufa )

Info

Publication number
EA200700614A1
EA200700614A1 EA200700614A EA200700614A EA200700614A1 EA 200700614 A1 EA200700614 A1 EA 200700614A1 EA 200700614 A EA200700614 A EA 200700614A EA 200700614 A EA200700614 A EA 200700614A EA 200700614 A1 EA200700614 A1 EA 200700614A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pufa
pharmaceutical composition
micro
fatty acids
composition containing
Prior art date
Application number
EA200700614A
Other languages
English (en)
Other versions
EA012371B1 (ru
Inventor
Паоло Карминати
Антонио Паренте
Original Assignee
Гп Фарм С.А.
Дефианте Фармасеутика, Лда.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гп Фарм С.А., Дефианте Фармасеутика, Лда. filed Critical Гп Фарм С.А.
Publication of EA200700614A1 publication Critical patent/EA200700614A1/ru
Publication of EA012371B1 publication Critical patent/EA012371B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Данное изобретение относится к фармацевтической композиции, содержащей суспензию, состоящую из масла с высокой концентрацией алкиловых эфиров полиненасыщенных жирных кислот (PUFA) и микрокапсул, содержащих по меньшей мере один полимер и статин.
EA200700614A 2004-10-19 2005-10-13 Фармацевтическая композиция, содержащая микрокапсулы статинов, суспендированные в алкиловых эфирах полиненасыщенных жирных кислот (pufa ) EA012371B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200402492A ES2255426B1 (es) 2004-10-19 2004-10-19 Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
PCT/ES2005/000542 WO2006045865A1 (es) 2004-10-19 2005-10-13 Formulación farmacéutica que comprende microcapsulas de estatinas suspendidas en ester alquílicos de ácidos grasos poliinsaturados (pufa)

Publications (2)

Publication Number Publication Date
EA200700614A1 true EA200700614A1 (ru) 2007-10-26
EA012371B1 EA012371B1 (ru) 2009-10-30

Family

ID=36227494

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700614A EA012371B1 (ru) 2004-10-19 2005-10-13 Фармацевтическая композиция, содержащая микрокапсулы статинов, суспендированные в алкиловых эфирах полиненасыщенных жирных кислот (pufa )

Country Status (22)

Country Link
US (1) US20090196920A1 (ru)
EP (1) EP1803440B1 (ru)
JP (1) JP4976302B2 (ru)
KR (1) KR101413339B1 (ru)
CN (2) CN102727462A (ru)
AT (1) ATE469641T1 (ru)
AU (1) AU2005298587B2 (ru)
BR (1) BRPI0516152A (ru)
CA (1) CA2583756C (ru)
CY (1) CY1110751T1 (ru)
DE (1) DE602005021668D1 (ru)
DK (1) DK1803440T3 (ru)
EA (1) EA012371B1 (ru)
ES (2) ES2255426B1 (ru)
IL (1) IL182466A (ru)
MX (1) MX2007004655A (ru)
NZ (1) NZ554265A (ru)
PL (1) PL1803440T3 (ru)
PT (1) PT1803440E (ru)
SI (1) SI1803440T1 (ru)
WO (1) WO2006045865A1 (ru)
ZA (1) ZA200703509B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610344A2 (pt) 2005-12-13 2016-11-29 Teva Pharma forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
AU2007245410A1 (en) 2006-04-26 2007-11-08 Rosemont Pharmaceuticals Ltd Liquid oral compositions
WO2008000731A2 (en) * 2006-06-26 2008-01-03 Valpharma S.A. Pharmaceutical composition for the oral administration of omega polyenoic fatty acids
CN101484144A (zh) * 2006-07-06 2009-07-15 特瓦特药工业有限公司 具有受控药物动力学的组合物
ITMI20072142A1 (it) 2007-11-08 2009-05-09 Yervant Zarmanian Composizioni farmaceutiche contenenti statine e derivati di acidi grassi omega-3
GB0724735D0 (en) 2007-12-19 2008-01-30 Psynova Neurotech Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
JP5421126B2 (ja) * 2008-01-10 2014-02-19 武田薬品工業株式会社 カプセル製剤
GB0818472D0 (en) * 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
ES2363964B1 (es) * 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
ES2363965B1 (es) * 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
ES2364011B1 (es) * 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
SG10201408508YA (en) 2009-12-23 2015-02-27 Defiante Farmacêutica S A Combination composition useful for treating cardiovascular diseases
CA2706270C (en) * 2010-06-03 2020-01-07 Accucaps Industries Limited Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
CA2706272C (en) 2010-06-03 2020-05-05 Accucaps Industries Limited Multi phase soft gel capsules, apparatus and method thereof
US8609138B2 (en) 2010-06-30 2013-12-17 Mochida Pharmaceutical Co., Ltd. ω3 fatty acid compound preparation
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
NZ727980A (en) 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
KR101466617B1 (ko) * 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
JP6173437B2 (ja) 2012-05-07 2017-08-02 オムセラ・ファーマシューティカルズ・インコーポレイテッド スタチン及びω−３脂肪酸の組成物
WO2013176455A1 (ko) 2012-05-22 2013-11-28 건일제약 주식회사 오메가-3 지방산 또는 그의 알킬 에스테르 및 스타틴계 약물을 함유하는 다층코팅 형태의 경구투여용 약학 조성물
CN102824636A (zh) * 2012-08-15 2012-12-19 四川大学 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途
WO2014182003A1 (en) * 2013-05-06 2014-11-13 Hanmi Pharm. Co., Ltd. Composite formulation comprising a film coating layer containing rosuvastatin or a pharmaceutically acceptable salt thereof
KR102240429B1 (ko) * 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형
WO2015185240A1 (en) 2014-06-04 2015-12-10 Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. Compositions containing simvastatin in omega-3 polyunsaturated fatty acids
RU2614734C2 (ru) * 2015-05-21 2017-03-28 Татьяна Алексеевна Денисюк Способ получения нанокапсул розувастатина в каррагинане
KR101950907B1 (ko) 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제
US11904054B2 (en) * 2018-01-19 2024-02-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents
WO2020068163A1 (en) 2018-09-24 2020-04-02 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
WO2022129002A1 (en) * 2020-12-15 2022-06-23 Dsm Ip Assets B.V. Coarse dispersion comprising statin and vitamin e oil
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312473B1 (ru) 1971-05-24 1978-05-01
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5035896A (en) 1988-06-15 1991-07-30 Warner-Lambert Company Water insoluble drugs coated by coacervated fish gelatin
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
WO2000057859A1 (en) 1999-03-31 2000-10-05 Abbott Laboratories Novel formulations comprising lipid-regulating agents
WO2000057918A2 (en) 1999-03-31 2000-10-05 Abbott Laboratories Novel formulations comprising lipid-regulating agents
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
WO2002043659A2 (en) * 2000-11-29 2002-06-06 Smithkline Beecham Corporation Composition containing statins and calcium for improved cardiovascular health
WO2002100394A1 (en) * 2001-06-12 2002-12-19 Galephar M/F Oral pharmaceutical composition containing a statin derivative
CA2456034A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
AU2003245313A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
GB0217306D0 (en) * 2002-07-25 2002-09-04 Novartis Ag Compositions comprising organic compounds
NZ539624A (en) * 2002-09-27 2008-08-29 Martek Biosciences Corp Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
JP2006521366A (ja) * 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド シームレスマイクロカプセルを含む固形経口剤形

Also Published As

Publication number Publication date
KR20070083715A (ko) 2007-08-24
CA2583756C (en) 2013-12-24
IL182466A (en) 2013-06-27
PL1803440T3 (pl) 2010-12-31
JP2008517040A (ja) 2008-05-22
CN102727462A (zh) 2012-10-17
DK1803440T3 (da) 2010-10-04
NZ554265A (en) 2010-12-24
BRPI0516152A (pt) 2008-08-26
PT1803440E (pt) 2010-08-31
AU2005298587B2 (en) 2010-08-05
ES2255426B1 (es) 2007-08-16
EA012371B1 (ru) 2009-10-30
IL182466A0 (en) 2007-07-24
ZA200703509B (en) 2008-09-25
SI1803440T1 (sl) 2010-10-29
MX2007004655A (es) 2008-03-10
DE602005021668D1 (de) 2010-07-15
EP1803440A1 (en) 2007-07-04
JP4976302B2 (ja) 2012-07-18
WO2006045865A1 (es) 2006-05-04
CA2583756A1 (en) 2006-05-04
CN101043873A (zh) 2007-09-26
ATE469641T1 (de) 2010-06-15
EP1803440B1 (en) 2010-06-02
US20090196920A1 (en) 2009-08-06
AU2005298587A1 (en) 2006-05-04
KR101413339B1 (ko) 2014-06-27
ES2255426A1 (es) 2006-06-16
CY1110751T1 (el) 2015-06-10
ES2347055T3 (es) 2010-10-25

Similar Documents

Publication Publication Date Title
EA200700614A1 (ru) Фармацевтическая композиция, содержащая микрокапсулы статинов, суспендированные в алкиловых эфирах полиненасыщенных жирных кислот ( pufa )
RU2014146111A (ru) Композиции статинов и омега-3 жирных кислот
JP2008522970A5 (ru)
ATE348140T1 (de) Lipasekatalysierte veresterung von fischoel
EA200300634A1 (ru) Фармацевтическая композиция, содержащая действующее вещество, диспергированное в матрице
FR2692283B1 (fr) Acid-anhydride esters as oil field corrosion inhibitors (ester acide anhidride comme inhibiteur de corrosion dans le domaine des huiles).
BRPI0517095A (pt) processos para preparação de composições de óleo
ATE419846T1 (de) Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese
ATE239717T1 (de) Ester und amide von nicht-steroidalen entzündungs-hemmenden carbonsäuren die als anti-oxidantien 5- lipoxygenase-hemmer und nicht-steroidale entzündungs-hemmende mittel verwendet werden können
MY141005A (en) Branched biodiesels
BRPI0515958A (pt) composição agroquìmica contendo éster de ácido fosfórico
DE602004021396D1 (de) Rwendung von glycerin
EA200401241A1 (ru) Форма для введения, включающая неустойчивое в кислой среде действующее вещество, единица действующего вещества, способ ее получения и микросфера
EA201500069A1 (ru) Способы уменьшения риска развития сердечно-сосудистого события у субъекта, получающего терапию статином
EP2602308A3 (en) Lipase-catalysed esterification of marine oil
EP2679687A3 (en) Fatty acid blends and uses therefor
DE60132508D1 (de) Zusammensetzungen enthaltend Phytosterol- und Policosanolester von Fettsäuren zur Herabsetzung des Cholesterol- und Triglyceridspiegels
BR0313876A (pt) Uso de uma mistura, composições de combustìvel e de solvente, e, processo para a preparação de uma mistura
NO20021919D0 (no) Fremgangsmåte til fremstilling av fettsyre-kalsiumsalter fra oljer med höyt glyceridinnhold
TW200601979A (en) Edible oil containing statins
ES2143067T3 (es) Procedimiento para la preparacion de esteres acrilicos refinados.
BR0207440A (pt) Formulações agroquìmicas
BR0109586A (pt) Composições contendo policarbonato
RU2012140651A (ru) Фармацевтический или нутрицевтический состав
DE69935798D1 (de) Veresterung von sauren rohölen

Legal Events

Date Code Title Description
PD1A Registration of transfer to a eurasian application by order of succession in title
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU